EGFR Exon 20 Insertion Mutation

Also known as: EGFR Exon20 Insertion Mutations

Drug	Drug Name	Drug Description
DB16695	Amivantamab	An EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.
DB16390	Mobocertinib	An oral kinase inhibitor targeted against EGFR and used in the treatment of NSCLC with EGFR exon 20 insertion mutations.

Drug	Drug Name	Target	Type
DB16695	Amivantamab	Epidermal growth factor receptor	target
DB16695	Amivantamab	Hepatocyte growth factor receptor	target
DB16695	Amivantamab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
DB16390	Mobocertinib	Epidermal growth factor receptor	target
DB16390	Mobocertinib	Cytochrome P450 3A4	enzyme
DB16390	Mobocertinib	Cytochrome P450 3A5	enzyme
DB16390	Mobocertinib	Cytochrome P450 3A7	enzyme
DB16390	Mobocertinib	P-glycoprotein 1	transporter
DB16390	Mobocertinib	ATP-binding cassette sub-family G member 2	transporter

Drug	Drug Name	Phase	Status	Count
DB00958	Carboplatin	1 / 2	Active Not Recruiting	1
DB00642	Pemetrexed	1 / 2	Active Not Recruiting	1
DB09330	Osimertinib	2	Not Yet Recruiting	1
DB14944	Tarloxotinib	2	Terminated	1
DB09330	Osimertinib	Not Available	Not Yet Recruiting	1